Fundsmith Equity Fund’s Thoughts on Novo Nordisk (NVO)

6 days ago 3

Soumya Eswaran

Mon, January 12, 2026 astatine 8:31 AM CST 3 min read

Fundsmith, an concern absorption steadfast based successful London, has released its yearly 2025 capitalist missive for its “Fundsmith Equity Fund.” A transcript of the missive tin beryllium downloaded here. The money focuses connected investing successful equities globally. The T Class Accumulation shares wherever the steadfast invested returned 0.8% successful 2025, compared to 12.8% for the MSCI World Index (‘Index’) successful sterling with dividends reinvested. Since its inception, the money has returned 1.7% p.a. much than the index. The money attributed its underperformance during 2025 to scale concentration, the maturation of assets successful Index Funds, and weakness successful the dollar. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its fourth-quarter 2025 capitalist letter, Fundsmith Equity Fund highlighted stocks specified arsenic Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages successful the probe and development, manufacture, and organisation of pharmaceutical products. The one-month instrumentality of Novo Nordisk A/S (NYSE:NVO) was 16.76%, and its shares mislaid 30.50% of their worth implicit the past 52 weeks. On January 9, 2026, Novo Nordisk A/S (NYSE:NVO) banal closed astatine $58.81 per share, with a marketplace capitalization of $263.8 billion.

Fundsmith Equity Fund stated the pursuing regarding Novo Nordisk A/S (NYSE:NVO) successful its 4th fourth 2025 capitalist letter:

"Novo Nordisk A/S (NYSE:NVO) managed to reaffirm my content that you should ne'er accidental ‘Things can’t get immoderate worse’. The institution has parlayed a marketplace starring presumption successful what is astir apt the astir breathtaking cause improvement for astir 3 decades into a secondary presumption and has failed to forestall amerciable generic contention successful its halfway US market.

Berenberg Lowers Novo Nordisk (NVO) Price Target to DKK 400, Maintains Buy Rating

Novo Nordisk A/S (NYSE:NVO) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 50 hedge money portfolios held Novo Nordisk A/S (NYSE:NVO) astatine the extremity of the 3rd quarter, which was 45 successful the erstwhile quarter. While we admit the imaginable of Novo Nordisk A/S (NYSE:NVO) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.